

Sanofi Patient Community Charter

June 2023



At Sanofi, we chase the miracles of science to improve people's lives. Our determination to find solutions for patients motivates us to develop breakthrough medicines and vaccines and work tirelessly around the world to bring these innovations to patients and communities.

Sanofi is a company that listens, acts, and leads with patients. We are committed to dialogue and maintaining open lines of communication with global communities.

We continue to improve the quality of our engagement with patient communities grounded within and by the local environment and realities in which we work. We conduct ourselves in a manner reflective of patient expectations to be seen, heard and felt, and in a manner consistent with our ethical values.

Our commitment goes beyond our medicines and vaccines. Sanofi recognizes that patients and individuals are more than their illness, disease or vaccine interest, and care about the broader, societal commitments of companies. We aim to build a healthier, more resilient world for our patients, communities, and our employees while minimizing the impact we, and our products, have on the planet.

This Charter deepens our commitments to the global patient and health communities we serve and formalizes our accountability in this regard. It was developed in collaboration with patients, caregivers, and advocacy organizations, and we will continue to consult, involve, and work with these communities as we deliver on this Charter and its commitments.

1 *We develop medicines and vaccines that reflect patient priorities and unmet needs*

Through collaborations with patients and caregivers, and by leveraging innovative, fit for purpose real-world data, health related goals are identified and incorporated into our research and development programs.

- Sanofi's research will be prioritized around the needs of the patient and health community.
- Our clinical studies will be designed to reflect assessments and outcomes that matter most to patients and individuals, while making it easier for individuals to participate via remote and digital capabilities and reducing, where possible, the number of visits and procedures required.
- Sanofi clinical trials will be representative of the communities they are meant to help.
- We will work with patient and health communities to increase clinical and data literacy, and access to quality care.

We report the following metrics annually:

- Percent (%) of pre-clinical priority research program and development stage indications where patient perspectives and health related goals are incorporated
- Clinical trials demonstrate improved accessibility, inclusivity, and diversity through:
 - % of clinical trial designs informed by patient and health community insights
 - % phase 2 and 3 clinical trials designed, with patient input, that include remote and digital solutions that make it easier to participate
 - % of clinical trials achieving their diversity recruitment goal
 - % of clinical trials and % of countries with a clinical trial literacy program

2 We partner with the advocacy community to better support them and the people they represent

We will maintain lean, efficient internal policies and processes to appropriately engage and build partnerships with advocacy organizations.

- We will engage in meaningful and timely dialogue with patient and health community organizations on scientific and access to care and prevention issues related to the disease area of interest for the organization.
- We will design patient and community programs and educational resources intended to support individuals on Sanofi products with patient and community input.
- We will collaborate with the community to identify and address barriers in the patient and caregiver pathways with respect to access to care and treatment.

We report the following metrics annually:

- Percent improvement as expressed by advocacy groups in the annual Sanofi Partnership Quality Survey* in the following categories:
 - Ease of use and experience with Sanofi processes
 - Sanofi communications on its science, access, and positioning on healthcare policies
- Percent of patient support programs developed with insights provided by patients, which reflect the local environment and address unmet needs
- Percent of development programs with an established Integrated Patient Journey

** The Annual Partnership Quality Survey covers over 380 patient organization partners across 15 countries*

3 *We improve and adapt our medicines and vaccines through real-world patient and health community insights*

- We will continually enhance our products and associated devices where possible and relevant for patient and health communities based on feedback we receive.
- We will generate ongoing insights and data, or evidence, on our products that is reflective of patient, caregiver and community interest and need.
- We will partner with advocacy organizations to define data gaps and generate innovative real-world data relevant to patient and health communities.

We report the following metrics annually:

- Percent of products, devices, support services and programs that are initiated or changed based on patient and health community feedback and reporting
- Continued research on our marketed treatments, vaccines, and devices will be directly informed by the patient and health communities they are meant to serve and measured by percent of 'Integrated Evidence Generation Plans' that took action on patient or health community insight
- The number of advisory boards with Patients and/or Patient Advocacy Leaders, the number of partnerships with Patient Advocacy Organizations, and the number and amount of our donations to Patient Advocacy Organizations

4 *We advocate for people-centered health care systems*

We partner with the patient and health care communities in the locations where we operate to advocate for public healthcare policies that prioritize patient insights and access to transformative medicines and vaccines:

- We will incorporate patient experience data in regulatory submissions and associated reimbursement dossiers.
- We commit to meaningful multi-stakeholder dialogue across all healthcare systems.

We report the following metrics annually:

- Percent of regulatory and health technology assessment filings where patient experience has been submitted as evidence
- Percent of Sanofi corporate Advocacy Papers and Statements that are informed by patient and health communities